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Abstract  
Purpose: Prognosis for patients with glioblastoma (GBM) remains poor, and new treatments are 
needed. Here we use a combination of two novel treatment modalities, carbon ions and a histone 
deacetylase inhibitor (HDACi). We compare these to conventional X-rays, measuring the increased 
effectiveness of carbon ions as well as radiosensitisation using HDACi.  
Materials and methods: Suberoylanilide hydroxamic acid (SAHA) was used at a non-toxic 
concentration of 0.5 µM in combination with 85 keV μm-1 carbon ions, and 250 kVp X-rays for 
comparison. Effects were assayed using clonogenic survival, γH2AX foci repair kinetics and 
measuring chromatin decondensation.  
Results: Dose toxicity curves show that human GBM LN18 cells were more sensitive to SAHA 
compared to U251 cells at higher doses, but there was little effect at low doses. When combined 
with radiation, clonogenic assays show that the Sensitiser Enhancement Ratio with carbon ions at 
50% survival (SER50) was about 1.2 and 1.5 for LN18 and U251 respectively, but was similar for X-
rays at about 1.3. The repair half-life of γH2AX foci was slower for cells treated with SAHA and was 
most noticeable in U251 cells treated with carbon ions where after 24 hr, more than double the 
number of foci remained in comparison to the untreated cells. Hoechst fluorescent dye 
incorporation into the nucleus showed significant chromatin decondensation and density 
homogenisation with SAHA treatment for both cell lines. 
Conclusions: Our results suggest a vital role of histone deacetylases (HDAC) in the modulation of 
DNA damage response and support the use of SAHA for the treatment of GBM through the 
combination with heavy ion therapy. 
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Introduction 
Suberoylanilide hydroxamic acid (SAHA or Vorinostat) is an epigenetic agent that inhibits both 
class I and class II deacetylases (HDAC). SAHA’s mode of action is primarily through chromatin 
modification, as hyper-acetylation of histones upon HDAC inhibition leads to chromatin 
decondensation. This generally leads to an upregulation of gene transcription in transformed cell 
lines (Gui et al. 2004), influencing a wide range of cellular processes including proliferation, 
apoptosis and DNA damage response (Minucci and Pelicci 2006).  
 
SAHA has been the first HDAC inhibitor (HDACi) to be approved by the United States Food and 
Drug Administration (FDA) for the treatment of relapsed and refractory cutaneous T-cell 
lymphoma (Dalgard et al. 2008; Gui et al. 2004). There have been a limited number of Phase I and 
Phase II clinical trials using SAHA on patients with recurrent glioblastoma, either as a single agent 
or in combination with other drugs (Chinnaiyan et al. 2012; Friday et al. 2012; Galanis et al. 2009). 
The results obtained so far suggest that SAHA is well tolerated and tumour progression, in some 
cases, has been delayed.  
 
SAHA has been shown to enhance radiosensitisation with conventional X-rays in a variety of 
cancer cell types both in vitro and in vivo with little or no toxicity to normal cells (Blattmann et al. 
2010; Dalgard et al. 2008). The mechanism of radiosensitisation is related to disrupted repair of 
DNA, leading to increased cell death (Groselj et al. 2013). It is known that SAHA can inhibit and 
down-regulate Rad51 which is crucial to DNA repair by homologous recombination (HR), while it 
also interferes with Ku70/Ku80 proteins involved in non-homologous end-joining (NHEJ) DNA 
repair. The consequence of this is the longevity of γH2AX foci (which signal regions of double 
strand breaks, DSB) in irradiated cells and their correlated radiosensitivity (Oertel et al. 2011; 
Blattmann et al. 2010). Interestingly, SAHA induces apoptosis in some cancer cells, but not in 
equivalent normal cells, when combined with either X-rays or carbon ions. It has been postulated 
that this unexpected finding is related to differing transcriptional regulation between cancer and 
normal cells (Qiu et al. 1999; Minucci and Pelicci 2006). In particular the cyclin-dependent kinase 
inhibitor 1 gene (p21WAF1), which in general prevents proliferation, is suppressed in many tumour 
cells but is upregulated by SAHA resulting in cell death (Gui et al. 2004).  
 
Heavy ion therapy (HIT) is an alternative radio-therapeutic modality to X-rays, characterized by a 
greater radiobiological effect for the same dose, normal tissue sparing due to the high energy 
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deposition in the Bragg Peak, and an increased efficacy of killing hypoxic tumour cells. 
Glioblastoma (GBM) brain tumour is a good candidate for treatment with HIT, as lower doses and 
a more confined treatment volume could spare vital eloquent areas of the brain, while greater cell 
killing in hypoxic areas could lower recurrence. Patients with GBM are routinely treated with 
concomitant X-rays and temozolomide (TMZ), but prognosis still remains poor (Barazzuol et al. 
2010). Previously, we have shown that TMZ causes reproducible additive cytotoxicity when 
combined with radiation, regardless of the radiation types and only on 06-methylguanine DNA 
methyltransferase (MGMT)-methylated GBM cell lines (Barazzuol et al. 2011), while ABT-888 (a 
poly (ADP-ribose) polymerase (PARP) inhibitor) radiosensitises all tested cell lines regardless of 
their MGMT status (Barazzuol et al. 2013). Despite advances in brain tumour treatment, it is clear 
that new therapies need to be developed to improve life expectancy. Importantly, it has been 
shown that SAHA can cross the blood-brain barrier and increase histone acetylation levels in the 
brain tissue (Hockly et al. 2003; Yin et al. 2007).  
 
Relatively few studies have investigated the radiosensitising effect of HDACi combined with carbon 
ions (Kano et al. 2009; Oertel et al. 2011). It is proposed that a major mechanism of SAHA 
radiosensitisation is through disrupting the repair and signalling response to DNA DSB. As carbon 
ions predominantly induce complex DSB through direct interaction with DNA while X-rays 
predominantly produce single strand breaks (SSB) through indirect interaction (by free radical 
production), it is thought that the efficacy of combining carbon irradiation with SAHA should be 
even greater than with X-rays. In this paper, we compare the effects of SAHA combined with 
carbon ion and X-ray irradiation on two GBM cell lines (LN18 and U251). 
 
Methods 
Cell lines and culture 
Human GBM U251 cells were obtained from the Health Protection Agency Culture Collections 
(HPACC, Salisbury, Wiltshire, UK) and Human GBM LN18 cells from the American Type Culture 
Collection (ATCC, Teddington, Middlesex, UK). The cells were cultured as previously described in 
Barazzuol et al. (2013). The doubling time for both cell lines was approximately 24 hours, whereas 
the plating efficiency was 63 ± 2% for LN18 and 24 ± 2.6% for U251.  
 
Drug Treatment 
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SAHA (Sigma-Aldrich, Poole, Dorset, UK) was reconstituted in pure MilliQ water. For the toxicity 
assay (Figure 1) the cells were cultured at an appropriate concentration of drug continuously for 
about 2 weeks. For radiosensitisation assays (Figure 2), SAHA was diluted to a concentration of 0.5 
µM in cell media and incubated with cells for 24 hr before the cells were irradiated, and removed 
directly after irradiation.  
 
Carbon ion irradiation 
Cells were irradiated using broad beam carbon ions provided by the Heavy Ion Medical Accelerator 
(HIMAC) at the National Institute of Radiological Sciences (NIRS), Japan, at an energy of 290 
MeV/u and a Linear Energy Transfer (LET) of 85 keV μm-1 on target, and a dose rate of 1Gy/min. 
The facility and broad beam irradiation procedure has been described elsewhere (Kanai et al. 
1999; Torikoshi et al. 2007). Cells were irradiated in either T25 flasks or microscopy flasks (Nunc, 
New York, USA) at a confluency of about 80%.  
 
X-ray irradiation 
X-ray irradiation was performed using a Gulmay machine operating at 250 kVp with a dose rate of 
0.65 Gy/min (Royal Surrey County Hospital, Guildford, UK).  
 
Clonogenic assay 
Clonogenic assays were used to evaluate the effect of SAHA with radiation. After irradiation, cells 
were seeded at an appropriate concentration for the dose received and grown in 6-well plates and 
incubated for up to 14 days. Colonies were fixed with 50% ethanol in Phosphate Buffered Saline 
(PBS) and then stained with 5% crystal violet in PBS (Sigma-Aldrich). Colonies with more than 50 
cells were counted and the survival fractions determined by taking into consideration the plating 
efficiency for all treatment modalities based on three separate experiments. 
 
γH2AX immunofluorescence 
Cells were grown in microscope flasks (Nunc) to about 80% confluence. Each slide was given 2 Gy 
of either carbon ions or X-rays. After irradiation, the cells were fixed in 2% paraformaldehyde in 
PBS at an appropriate time point (these were as follows: 1, 2, 6, 12 and 24 h). For γH2AX and DNA-
dependent protein kinase catalytic subunit (DNA-PKcs) phospho T2609 immunostaining, the cells 
were permeabilised with 0.2% Triton-X, washed twice with ice-cold PBS and incubated with 1% 
Bovine Serum Albumin (BSA) in PBS for 1 hr, before being probed with anti-γH2AX antibody 
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(Millipore, Watford, UK) and DNA-PKcs (phospho T2609) (Abcam, Cambridge, UK) both at a 
dilution of 1:200 in 1% BSA in PBS for 1 hr at room temperature. Cells were then washed three 
times with PBS before adding Alexa Fluor 488-conjugated goat anti-mouse Immunoglobulin G 
secondary antibody (Millipore) at a dilution of 1:400 in PBS for 1 hr, protected from light. Cells 
were washed three times with PBS before adding 0.5 μg/ml propidium iodide (PI; Invitrogen Life 
Sciences, Carslbad, CA, USA) in PBS for 5 min. Finally, coverslips were mounted with 10 μl of 
ProLongGold anti-fade reagent (Invitrogen). Foci scoring was carried out using a in-house and a 
Nikon fluorescence microscope. At least 100 cells per sample were chosen at random on the slide 
and the γH2AX foci were counted by eye on single plane images. 
 
Measuring nuclei area and peak fluorescence brightness 
Cells were treated with 0.5, 5 or 10 µM of SAHA for 24 hr in 35 mm Petri dishes. The cells were 
then incubated for 1 hr using 2 µM Hoechst 33258 (Invitrogen) to stain the nucleus of live cells. A 
fluorescent microscope with a XY stage was used to take images of at least 1000 cell nuclei for 
each of the conditions. Cells were imaged using a EMCCD camera model C9100-13 (Hamamatsu, 
Tokyo, Japan), with an exposure time of 30 ms and gain of 3.0, with the fluorescent output of the 
mercury arc lamp set to 50%. Images were standardised by imaging an Yttrium Aluminum Garnet 
doped with Cerium (YAG:Ce) scintillator which fluoresces in both blue and green wavelengths. The 
intensity recorded from the scintillator was used to normalise fluorescent intensity across the field 
of view of the microscope, and to normalise between images. Pixels within cells above an 18% 
intensity threshold were recorded. The time duration of imaging all dishes was small, so 
degradation of the mercury arc lamp, or bleaching of the YAG:Ce scintillator over this time period 
can be assumed to be negligible. The images were ultimately analysed using a custom made 
software to measure the area and the peak intensity of the nuclei (Barber et al. 2007).  
 
Statistical analysis 
All of the experiments were repeated in triplicate on at least two separate days. The results are 
averaged and the standard error of the mean is given. All curve fittings were performed in 
OriginPro (Northampton, MA, USA) with an optimisation of the fit weighted to the variance of the 
data points.  
 
Where appropriate, statistical significance was determined using a two-sample t-test and p-values 
less than 0.05 were considered significant.  
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The toxicity of SAHA to the cell lines (see Figure 1) was fitted with a Hill equation: 
      
  
     
 
Where Vmax is the saturation drug concentration, k is a constant which is half of the Vmax, c is the 
drug concentration, and n is the Hill coefficient describing cooperativity. 
 
The Linear-Quadratic (LQ) equation was used to fit clonogenic survival data (see Figure 2): 
          
 
 
Where α defines the linear component, β relates to the quadratic component, and d is the 
radiation dose.  
 
A two component exponential model was used to fit the γH2AX repair kinetics data (see Figure 3), 
adapted from Horn et al. (Horn et al. 2011). To calculate the half life of the fast (T1/2Fast) and slow 
(T1/2Slow) component, each component was multiplied by the natural logarithm of 2:  
          
          
      
Where A is the amplitude of the curve, τ1 and τ2 are the mean lifetime constants and x is the time 
in hours.  
 
The Sensitiser Enhancement Ratio (SER) was given using the following formula (see Table I): 
       
               
            
 
Where dosex%(no drug) is the radiation dose (Gy) required to produce ×% cell survival without drug 
and dosex%(drug) in presence of drug (i.e. SAHA). SER was calculated at doses related to surviving 
fractions of 37 and 50%. 
 
The relative biological effectiveness at 10% survival (RBE10%) is given using the following formula: 
         
                
                     
 
Where the dose is measured in Gy.  
 
Results 
SAHA sensitivity 
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Figure 1 shows the sensitivity of both cell lines, LN18 and U251, to continuous SAHA exposure with 
different concentrations. The Hill model fit to the data shows that LN18 cells are just over three 
times more sensitive than U251 with a half-maximal cytotoxic concentration (CC50) of 9.77 ± 0.87 
µM compared to 36.99 ± 0.88 µM for U251. However, treatment for 24 hr with 0.5 µM SAHA, 
rather than continuously, does not affect the plating efficiency for either cell line (data not 
shown). This non-toxic regime was used for all radiosensitisation experiments. Importantly, the 
concentration of 0.5 µM SAHA is clinically relevant, in accordance with the peak plasma 
concentration and the area under the plasma drug concentration-time curve measured after a 
daily dose of 500 mg (Kelly et al. 2005; Lee et al. 2012).  
 
X-ray and carbon ion sensitivity 
Figure 2 shows survival curves for both cell lines treated either with or without SAHA and 
irradiated with either X-rays or carbon ions. Table I shows the fits of these data to the LQ equation 
giving the α and β parameters. 
 
Both cell lines have largely similar radiosensitivities to X-rays; however, they do also display some 
differences; U251 has a smaller α (and so a larger “shoulder”) and a slightly larger β parameter. In 
general, this means that U251 are more capable of fixing sub-lethal damage (attributed to the 
“shoulder”) but have a reduced ability to fix complex DNA breaks, attributed to a large β-
parameter (Hall and Giaccia, 2006).  
 
U251 is slightly more resistant to carbon ions than LN18. This is reflected by a lower RBE10% of 3 ± 
0.6 for U251 and 3.5 ± 0.6 for LN18 (see Table I). The survival curve for U251 again has a 
noticeable “shoulder”, whereas the LN18 data can be fitted using only the α parameter (i.e. no 
“shoulder”) which accounts for the slight difference in the RBE value.  
 
SAHA radiosensitising effect 
Table I shows the Sensitiser Enhancement Ratio (SER) for SAHA in combination with X-rays or 
carbon ions at 50% (SER50) and 37% (SER37) survival. For both cell lines and radiation qualities, 
radiosensitisation is greater at higher doses. Radiosensitisation with X-rays is very similar between 
cell lines with a SER50 of about 1.3. For LN18, X-rays produce more radiosensitisation than carbon 
ions (SER50 values being 1.31 and 1.19 for X-rays and carbon ions, respectively) whereas for U251 
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the effect is reversed (SER50 values being 1.37 and 1.55 for X-rays and carbon ions, respectively). 
Similar effects are also suggested by the prolonged γH2AX foci expression.  
 
γH2AX foci repair kinetics 
The foci repair kinetics (Figure 3) after 2 Gy X-rays are similar between the two cell lines with both 
having a fast and slow foci repair half-life of between 0.5 and 1 hr and between 15 and 30 hr, 
respectively. The absolute numbers of foci with untreated cells are broadly similar too, starting 
with about 20 foci at 1 hr with no SAHA and finishing with fewer than 5 foci at 24 hr. However, 
both cell lines treated with SAHA consistently have on average about 2-5 more foci than their 
untreated counterparts. This is probably because cells treated with SAHA have a slightly larger 
T1/2Slow component, resulting in a slower foci repair rate.  
 
The situation is different for cells irradiated with 2 Gy carbon ions. For LN18 cells, SAHA makes 
little difference to the repair kinetics and also does not increase the number of foci significantly. 
However for U251, SAHA increases the slow repair half-life from about 15 to 50 hr. This is 
reflected in the absolute number of foci remaining at 24 hr, where the SAHA-treated U251 cells 
have more than double the number of foci remaining compared to the untreated counterpart 
(p=0.001). Thus, overall, SAHA appears to slow the repair of DSB, indicated by the comparative 
longevity of foci. It should also be noticed that single exposure to 0.5 µM SAHA did not increase 
the background level of γH2AX foci up to 24 hr after treatment, which varies between 0.08 and 0.1 
foci/cell for both cell lines. 
The recruitment of DNA repair proteins at sites of DSB involves histone acetylation, ubiquitination 
and chromatin remodelling. To investigate how SAHA might affect this process, in particular foci 
formation, we assessed the number of both γH2AX and DNA-PKcs (phospho T2609) showing that 
both these proteins are similarly recruited to DSB in cells incubated with or without SAHA prior to 
irradiation with 2 Gy X-rays (p>0.05; Figure 3F).  
 
Effect of SAHA on Hoechst dye binding to DNA  
Measuring the nucleus area and the DNA peak fluorescence (maximum brightness) of nuclei 
indicates the extent of chromatin reorganisation and decondensation caused by SAHA. Generally, 
cells will stain heterogeneously with Hoechst dye, as denser chromatin (heterochromatin) regions 
will contain more dye.  
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Figure 4 shows boxplots of the variation in fluorescent peak intensity in the nucleus after 
treatment with various concentrations of SAHA, with each box representing about 1000 cells. If 
the peak intensity is high, there are regions in the nucleus which are highly compacted and 
concentrate the Hoechst dye. Overall, Figure 4 shows that the DNA dye intensity decreases with 
increasing concentrations of SAHA. This indicates that SAHA is relaxing the chromatin and creating 
a more homogeneous and decondensed chromosomal structure. In particular, LN18 cells have less 
bright regions than U251 cells, and also an incremental decline in the intensity with increasing 
concentration of SAHA. The situation is similar with U251 cells, although there is no significant 
difference between cells treated with 5 and 10 µM. The pertinent point is that 0.5 µM SAHA, 
which is used in the present paper in combination with radiation, significantly relaxes the 
chromatin (p << 0.05).  
 
Discussion 
The results presented here show that SAHA is an effective radiosensitiser with both X-rays and 
carbon ions. The greatest sensitivity is observed in U251 cells when irradiated with carbon ions. 
SAHA in combination with X-rays increases cell killing by about 30% for both cell lines compared to 
X-rays alone. While for carbon ions in combination with SAHA the cell killing is increased by cell 
about 20% for LN18 and 55% with U251 when compared to carbon ions alone.  
 
The radiosensitising effect is in some measure related to unrepaired DNA DSB. γH2AX foci assays 
show that SAHA treated cells have consistently higher numbers of foci than their untreated 
counterparts. The main reason for this is probably the slower rate of DNA DSB repair when SAHA is 
present. The slower rate of repair is most evident for U251 cells treated with carbon ions and 
SAHA. Here, more than double the foci remain after 24 hr with the slow component of the repair 
rate more than three times slower compared to cells not treated with SAHA. This shows that U251 
cells, particularly in the presence of SAHA, have difficulty in repairing the predominantly complex 
DNA strand breaks that result from carbon ion treatment. Nakajima et al. (2014) analysed the 
morphology, intensity and size of foci from 70 keV µm-1 Carbon ions and 200 keV µm-1 Fe ions. It 
was found that clusters of γH2AX foci radiated outwards from the original track caused by 
secondary short range delta-electrons. These foci are repaired with DNA non-homologous end-
joining (NHEJ) kinetics in G1 phase, with the magnitude of complexity diminishing with time. This 
reflects the two component repair kinetics that we have shown in Figure 3. 
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The effect of carbon ions and SAHA in terms of γH2AX foci is not so pronounced on LN18 cells, 
which could be due to this cell line being more efficient at DSB repair in the presence of SAHA. 
However, the RBE10 is slightly higher with LN18 cells compared to U251 (3.5 compared to 3.0) with 
a comparable difference in cells treated with SAHA. Intuitively, we should have expected U251 to 
be more sensitive to carbon ions owing to their slower DNA repair rate in presence of SAHA. 
However, 2 Gy of carbon ions (see Figure 2) killed the majority (> 95%) of the irradiated cells of 
both cell lines in either treatment scenario and therefore it was difficult to detect any variation 
induced by SAHA in terms of RBE10 at very low survival levels. 
 
Fluorescent dye incorporation into the nucleus with increasing concentrations of SAHA showed 
decreasing levels of DNA peak brightness, indicating substantial decondensation of the 
chromosomes and a more homogeneous chromatin arrangement. The chromatin structure and its 
arrangement in the nucleus directly influences the expression of genes (Felsenfeld and Groudine, 
2003). The repeating unit of chromatin consists of approximately 146 base pairs of two 
superhelical turns of DNA wrapped around an octamer core of pairs of histones, H2A, H2B, H3 and 
H4. The histones can be modified including the acetylation of lysine, methylation of lysines and 
arginines and phosphorylation of serines. Histone deacetylases (HDAC), in part, determine the 
pattern of histone acetylation within the nucleus. Inhibition of HDAC, by agents such as SAHA, 
causes an accumulation of acetylated histones. Acetylated histones are associated with a 
neutralisation of the lysine positive charge leading to the chromatin becoming less dense. In 
general, this allows for greater access to promoter regions of genes and consequent upregulation 
in gene expression.  
 
Growing evidence shows that HDACi selectively kill cancer cells at levels which are non-toxic to 
normal cells. This is because chromatin relaxation allows transcription of genes which induces 
growth arrest or apoptosis. Gui et al. (2004) showed that p21WAF1 (which regulates cell cycle 
checkpoints and ultimately proliferation) is upregulated in ARP-1 tumour cells in the presence of 
SAHA. This work was corroborated by Belluci et al. (2013) who found that activation of p21WAF1 
requires acetylation of the histone H2A.Z. Moreover, Conti et al. (2010) found that SAHA can slow 
down replication forks, induce DNA damage and activate dormant origins of DNA replication, 
specifically decreasing the expression of HDAC3. Toth et al. (2004) showed that the HDACi 
trichostatin A (TSA) caused decondensation of interphase chromatin and increased apoptosis with 
HeLa cells. Interestingly, they showed that a number of HDAC must be inhibited simultaneously 
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and cooperatively to explain the apoptosis increase that was measured with increasing 
concentrations of TSA. Hence, it is highly likely that the toxicity seen with HDACi stems from 
genome wide action on the regulation of a number of genes simultaneously. About 20% of all 
known genes are affected by HDAC inhibition and the ratio of upregulation and downregulation is 
close to 1:1 (Minucci and Pelicci 2006). Following exposure to SAHA, gene expression analysis on 
colon cells and mesenchymal stem cells has revealed a wide range of upregulated and 
downregulated genes (Di Bernardo et al. 2010; LaBonte et al. 2009). While in general DNA repair 
proteins like Ataxia telangiectasia mutated (ATM), and Rad51 are downregulated inhibiting DNA 
repair efficiency, on the contrary cell cycle genes, such as p21, are generally upregulated by SAHA 
causing an aberrant cell cycle arrest that may lead to apoptosis (Richon et al. 2000). 
 
Not only are promoters of genes more accessible in the presence of HDACi, but HDAC inhibition 
can also modify acetylation sites on non-histone proteins, changing their function. For example, 
Roy et al. (2005) showed that p53 can be stabilised in the presence of an HDACi (CG-1521) after 
acetylation, leading to increased cell cycle arrest and apoptosis in prostate cancer cells. Similarly, it 
has been found that SAHA blocks the protein Rad51 from co-localising with γH2AX DSB foci and 
thereby preventing repair (Chen et al. 2012). It was found that the Rad51 protein’s function itself 
was disrupted independently of the transcribed amount of protein available. Moreover, the 
baseline level of Rad51 was reduced with SAHA treatment. It was also found that SAHA selectively 
inhibited the homology-directed repair pathway, but interestingly, not the NHEJ pathway. 
Similarly, Harikrishnan et al. (2008) found that the HDACi, valproic acid, induced histone 
independent disruption which contributed to the radiosensitising effects on cells, although exactly 
which proteins were responsible for this effect were not identified.  
 
Similarly to our results, Camphausen et al. (2004) used a HDACi, MS-275, and found that it 
radiosensitised U251 cells by about 30% when combined with X-rays. Moreover, a significantly 
greater number of cells were γH2AX positive at 24 hr after 5 Gy, although at 6 hr there were 
similar numbers of foci to the untreated counterparts. Interestingly, the radiosensitisation was 
greater for a prostate cancer cell line than the U251 cell line, although no reason was given for 
this. It was unclear whether MS-275 affected the acetylation status of H2AX, or whether an 
upstream component was disrupted so that DSB repair was impeded. In the light of Chen et al. 
work, it is likely that the HR pathway is disrupted, with Rad51 being impeded. Either way, it is clear 
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that cell lines are prone to DSB repair disruption by HDACi, and the extent of this is cell line 
dependant. 
 
To our knowledge, there have only been two previous reports of HDACi and radiosensitisation 
with carbon ions. Kano et al. (2009) used cyclic hydroxamic-acid-containing peptide 31 (CHAP31) 
and 50 keV µm-1 carbons ions and showed about a 50% enhancement with squamous cancer cells. 
Importantly, they also showed that p21WAF1 was upregulated in the presence of CHAP31. Similarly, 
Oertel et al. (2011) combined SAHA and carbon ions (the LET was not given) and found similar 
levels of radiosensitisation between carbon ions and conventional X-rays. Moreover, they also 
found that p21WAF1 was upregulated in the presence of SAHA while p53 was unaffected. Cell cycle 
analysis revealed that cells were blocked in G1 or G2/M, while γH2AX foci repair kinetics showed 
cells with significantly more foci after SAHA and carbon treatment than their un-irradiated 
counterparts.  
 
Substantial evidence supports the hypothesis that HDACi can sensitise cancer cells to ionising 
radiation, to greater or lesser extents depending on the cell line. The main reason for this appears 
to be the inability of treated cells to repair DNA breaks, probably by the interference with Rad51 
and the HR pathway. Coupled with this is the upregulation of p21WAF1 in cancer cells with HDACi, 
causing cell cycle delay and increased propensity for apoptosis. The mechanism of 
radiosensitisation is probably related to a combination of both of these factors, and probably 
influenced by other disrupted pathways yet to be identified. In general, it does not appear that 
significant additional radiosensitisation is generally achieved using high-LET radiation over 
conventional X-rays. However, there is some evidence that complex DNA DSB caused by high-LET 
radiation or high doses of X-rays, are less easily fixed in the presence of an HDACi. Hence, the 
SER37 is less than that at SER50. In this way, the sensitising enhancement ratio at a clinically 
relevant dose (i.e. 2 Gy fraction) may have a higher efficacy with carbon ions than with X-rays, as 
high-LET radiation clusters DNA damage causing complex breaks.  
 
Conclusions 
In the present paper, it has been shown that SAHA is an effective radiosensitiser when used in 
combination with either X-rays or carbon ions on GBM cancer cells, and can enhance cell death up 
to 50% more than controls. Compared to X-rays alone, the combination of carbon ions and SAHA 
can increase the RBE10% by more than 3.5 times. This is a significant finding as GBM is one of the 
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most aggressive forms of cancer with a mean survival rate of about one year, even when treated 
with X-rays and TMZ. Thus, a combination of SAHA and radiation of either high or low LET quality 
might represent a potentially effective treatment strategy for patients with GBM, with the 
additional benefit that high LET radiation could limit normal tissue toxicity as normal tissues are 
receiving less radiation and therefore any possible SAHA-mediated radiosensitizing effect on 
normal cells is further reduced. The mechanism of radiosensitisation with SAHA is not completely 
clear, but the results presented in this paper show that it is partially due to the interference of DSB 
repair as demonstrated by greater γH2AX foci in SAHA-treated cells. However, the global effect 
that SAHA has on the nucleus, as exemplified by the decondensation of the chromatin, means that 
many possible pathways are affected which could lead to cancer cell radiosensitisation.  
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Figure legends 
 
Figure 1: The sensitivity of two GBM cell lines (LN18 and U251) after continuous incubation with 
SAHA. The data have been fitted with the Hill equation. Error bars indicate the standard error of at 
least three independent experiments. 
Figure 2: (A) LN18 and (B) U251 cells irradiated with either 250 kVp X-rays or 85 keV μm-1 carbon 
ions with and without 0.5 µM SAHA. Error bars indicate the standard error of at least three 
independent experiments. 
Figure 3: (A-D) DNA repair kinetics of cells irradiated with X-rays or carbon ions measured using 
γH2AX foci. The data are fitted with a two component exponential model (see methods). The 
approximated half-life of the repair time for the fast and slow component is given in the legend (A) 
LN18 cells irradiated with either 250 kVp X-rays or (B) 85 keV μm-1 carbon ions with and without 
SAHA. (C) U251 cells irradiated with either 250 kVp X-rays or (D) 85 keV μm-1 carbon ions with and 
without SAHA. Error bars indicate the standard error of at least three independent experiments. 
(E) Representative images of γH2AX formation in U251 cells at 0.5 hr after irradiation with 2 Gy X-
rays with and without SAHA. (F) Representative images of DNA-PKcs (phospho T2609) foci in U251 
cells at 0.5 hr after irradiation with 2 Gy X-rays with and without SAHA. Nuclei were stained with PI 
(red). The white scale bar is 10 µm.  
Figure 4: The effect of SAHA on the binding of Hoechst DNA dye in the nuclei of (A) LN18 and (B) 
U251 cells with varying concentrations of SAHA. The fluorescent peak intensity measures the 
brightest collection of pixels in the nucleus, and is an indication of densely compacted chromatin. 
The boxes show the median, 25 and 75 percentiles, the whiskers and crosses show the 5 and 95, 1 
and 99 percentiles respectively, and the squares show the mean. With both cell lines, the mean of 
the control and cells treated with 0.5 µM SAHA are significantly different at p = 0.05, using a 
Student’s t-test. (C) Representative images of Hoechst 33258-stained U251 cell nuclei treated with 
different concentration of SAHA (0, 5 and 10 µM). Nuclei within red squares were identified by the 
microscope system described in Methods. The white scale bar is 10 µm. 
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Table legends 
Table I: Mean values and standard errors of α, β, SER50, SER37 and RBE10 estimated by fitting the 
cell survival data of Figure 2 to the LQ model. 
 
Supplementary figure legends 
Supplementary Figure S1: Representative images of DSB repair at 0.5, 2, 6, 12 and 24 hr post 
irradiation with 2 Gy Carbon ions with and without SAHA. Images were captured using a Nikon 
fluorescence microscope. The white scale bar is 10 µm.  
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Table 1: Mean values and standard errors of α, β, SER50, SER37 and RBE10 estimated by fitting the cell survival data of Figure 2 to the LQ model. 
 
 LN18 U251 
 α (Gy-1) β (Gy-2) SER50 SER37 RBE10 α (Gy-1) β (Gy-2) SER50 SER37 RBE10 
X-rays 0.10 ± 0.03 0.04 ±0.01     0.005 ± 0.02 0.06 ± 0.01     
X-rays + 0.5 µM SAHA 0.20 ± 0.03 0.03 ± 0.01 1.31 ± 0.06  1.25 ± 0.05   0.14 ± 0.03 0.06 ± 0.01 1.37 ± 0.06 1.29 ± 0.06   
C ions 1.38 ± 0.05 0   3.5 ± 0.6 0.53 ± 0.09 0.34 ± 0.05   3.0 ± 0.6 
C ions + 0.5 µM SAHA 1.60 ± 0.05 0 1.19 ± 0.07 1.18 ± 0.06 3.9 ± 0.6 1.19 ± 0.1 0.09 ± 0.06 1.55 ± 0.09 1.41± 0.08 3.3 ± 0.6   
 
